ATLATL Innovation Center

What ATLATL Innovation Center does

ATLATL Innovation Center operates a multi-regional life sciences R&D platform anchored in the Asia-Pacific region. Founded in 2017 and headquartered at Shanghai's Zhangjiang Pharma Valley, the company runs an integrated real estate plus CRO model that combines turnkey Class A laboratory and office space with on-site contract research services and 11 specialized R&D platforms — Animal Research (in partnership with Charles River CRADL), Cell & Gene Therapy, Cell Manufacturing (Miltenyi CliniMACS-based), Drug Screening, Exosome & EV, FACS & Sorting, Imaging (Nikon, Revvity, Akoya), Multi-Omics, Organoid, Pathology, and Single Cell / Spatial Biology (Bruker CosMx, Vizgen MERSCOPE Ultra). The flagship Shanghai Zhangjiang facility spans 270,000 square feet and is positioned as the largest shared Class A laboratory footprint in APAC, with additional centers in Beijing (Changping), Shenzhen (Greater Bay Area), Ningbo, Hong Kong, Singapore, and Brisbane (co-located with QIMR Berghofer).

The company generates revenue through four streams: (1) Lab Space as a Service — recurring rental of fully furnished lab modules, private suites, and co-working space on flexible or annual terms; (2) On-site CRO Services including gene and protein services, cell biology, and analytical services delivered via project-based contracts; (3) R&D Platform Access fees for use of the 11 specialized centers; and (4) Cloud Lab managed services, which allow remote clients to commission experiments executed by ATLATL scientists with AI-assisted experimental design and real-time data access. Pricing is not publicly disclosed and is configured per client. ATLATL's primary customer segments are early-stage biotech startups and multinational pharmaceutical companies (with growth-stage biotech and research institutions as a secondary segment). Strategic customers and open-innovation partners include Samsung Bioepis, Daiichi Sankyo, and Servier, which channel deal flow into ATLATL's centers and co-fund programming such as the Samsung Bioepis Innovation Prize C-Lab Outside and the Servier Co-Lab award (800,000 RMB in lab/R&D services).

The company's GTM motion is enterprise B2B, relationship-driven, and executed through direct outreach, executive-level pharma partnerships, conference participation, and a multilingual corporate website with tour scheduling. ATLATL also operates ATLATL Ventures, a coordinated innovation fund matrix providing early investment capital alongside platform access. While ATLATL does not disclose revenue, funding rounds, or headcount beyond a corporate 11-50 range, the combination of multi-site infrastructure, a bundled CRO-and-real-estate offering, and marquee pharma open-innovation partnerships positions it as a category-defining APAC life sciences platform.

Name

ATLATL Innovation Center

Legal name

ATLATL Innovation Center

Website

https://atlatl.center

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

ATLATL Innovation Center is a private, APAC-based life sciences R&D platform founded in 2017, operating seven integrated innovation centers across China, Singapore, and Australia. It bundles turnkey Class A laboratory space, 11 specialized R&D platforms, and on-site CRO services for early-stage biotech startups and multinational pharmaceutical partners including Samsung Bioepis and Daiichi Sankyo.

Ownership category

akta.pro rank

Product category

Life Science R&D Infrastructure

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), Laboratory Apparatus & Furniture (3821)

akta.pro primary industry

Clinical Research & Trial Central Laboratories (HLAFAMAL)

akta.pro secondary industries

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Laboratory, Bioanalytical & Central Lab Staffing FSP (HLAGAOAI), Life Sciences & Biotech (R&D/Clinical) Staffing (BPACADAL)

Keywords

• Life science lab space
• Biotech R&D services
• Shared laboratory facilities
• Contract research organization
• Lab space as a service

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Infrastructure, Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Lab Space as a Service (Lab SaaS): Provides fully furnished, turnkey Class A laboratory and office space to life science startups and companies. Revenue is generated through rental of lab modules, private lab suites, and co-working spaces on flexible or long-term terms.
2. On-site CRO Services: Contract research organization services delivered on-site, including gene and protein services, cell biology services, analysis services, and specialized platform services. Revenue is earned through project-based service contracts with biotech clients.
3. R&D Platform Access: Revenue from access to specialized R&D platforms and core facilities including drug screening, multi-omics, organoid, imaging, FACS, pathology, cell manufacturing, and cell & gene therapy centers.
4. Cloud Lab Services: Remote R&D execution services where ATLATL scientists conduct experiments on behalf of clients, with project directors and real-time data access provided to clients globally.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

ATLATL Innovation Center operates turnkey Class A laboratory and office space for life sciences startups, paired with on-site CRO (contract research organization) services and 11 specialized R&D platforms spanning multi-omics, imaging, pathology, cell and gene therapy, drug screening, single-cell research, and animal research. The integrated platform enables biotech innovators to launch day-one without capital investment in lab buildout, with optional remote execution via its AI-enabled Cloud Lab across a multi-regional Asia-Pacific network.

Product overview

ATLATL Innovation Center is a global life science R&D platform offering an integrated ecosystem combining physical infrastructure (Class A labs, office space) with 11 specialized research platforms and on-site CRO services. The core platform integrates lab space-as-a-service with specialized centers including Animal Research (CRADL), Cell & Gene Therapy, Cell Manufacturing, Drug Screening, Exosome/EV, FACS & Sorting, Imaging, Multi-Omics, Organoid, Pathology, and Single Cell Research centers. Supporting services include Gene & Protein services, Cell Biology services, Analysis services, and Cloud Lab for distributed execution. ATLATL Ventures provides investment support for biotech companies. The platform operates across key APAC markets including Shanghai, Beijing, Shenzhen, Hong Kong, Singapore, and Australia.

Differentiator

Problem solved

Functional benefit

Brands

• Servier Co-Lab: A collaborative innovation program with Servier (French pharmaceutical company) targeting early-stage biotech innovations in Greater China, focused on oncology and neuroscience precision medicine projects.

Products and services

• Lab Space Turnkey Class A laboratory space offered by layout (monomer, dimer, polymer modules) and by compliance level, providing life science startups immediate access to fully equipped lab infrastructure without capital outlay.
• Office Space Fully furnished office suites and workspace for teams of 4-10 people, with private offices, customized offices, hotdesks/co-working, and virtual office options for biotech tenants.
• Cloud Lab Remote R&D execution platform that allows scientists to design, monitor, and manage experiments from anywhere, with dedicated project directors, on-site technical teams, and AI-driven experimental design and workflow optimization tools.
• Gene & Protein Services On-site CRO service offering gene synthesis, protein expression (E. coli, insect, mammalian, yeast), protein purification, activity assays, and antibody services for biotech researchers.
• Cell Biology Services Cell biology research services covering cell culture, transfection, imaging, intracellular molecular assays, flow cytometry, custom cell development, and immune cell function testing.
• Analysis Services Molecular, cellular, tissue, and in vivo analytical services supporting target validation, mechanism studies, biomarker discovery, PK/PD, and translational research.
• Animal Research Center (CRADL) Vivarium/animal research facility operated in partnership with Charles River (CRADL), providing standard and immunodeficient animal models, surgical/induced models, and humanized models at cage-level, room-level, or private suite configurations.
• Cell & Gene Therapy Center Integrated platform combining cell engineering, gene editing (CRISPR-based), viral vector development (lentivirus, AAV), and non-viral delivery systems for CAR-T/TCR-T development, gene editing, and stem cell projects.
• Cell Manufacturing Center CliniMACS-based closed system technology platform supporting scalable, standardized manufacturing of autologous and allogeneic cell therapies with GMP-compliant workflows for T cell, NK cell, Treg, B cell, and HSC isolation.
• Drug Screening Center High-throughput screening platform integrating automation, advanced assay technologies, and biology-relevant models for lead compound identification, target validation, and proof-of-concept data generation.
• Exosome & EV Center Integrated end-to-end platform for exosome-based therapeutics and delivery systems covering isolation, characterization, functional validation, and scalable production from cell culture, plasma, and urine samples.
• FACS & Sorting Center Multi-parameter flow cytometry and sterile closed-system cell sorting platform for precise identification and separation of cell populations from complex samples, supporting immunophenotyping and cell therapy workflows.
• Imaging Center Advanced microscopy, high-content imaging, and in vivo imaging systems platform for studying biological processes across molecular, cellular, and whole-animal levels.
• Multi-Omics Center Integrated platform combining genomics, transcriptomics, proteomics, and metabolomics with spatial technologies to capture complete biological processes from genetic to functional outcomes.
• Organoid Center Organoid, organ-on-chip, and multi-cell co-culture model platform for drug efficacy, safety, and mechanism evaluation including tumor microenvironment, ADME, and barrier/drug delivery assessments.
• Pathology Center Integrated core laboratory providing comprehensive services including histology, immunohistochemistry, molecular analysis, and microscopy evaluation for human tissue-based research studies.
• Single Cell Research Center Spatial multi-omics and live single-cell functional analysis platform enabling researchers to map cell types, states, and microenvironment interactions in human tissue with real-time isolation and testing capabilities.
• ATLATL Ventures Industry and capital-driven coordinated innovation fund matrix supporting biotech and healthcare ventures with platform access, R&D acceleration, and early investment capital utilization.

Quantifiable outcome

• Faster proof-of-concept timelines through integrated R&D execution

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature7 records

Partnerships

Twelve partnerships are on record, tiered core, strategic and supporting.

• Samsung BioepiscoreStrategic or Co-development Partner · 29 April 2026Samsung Bioepis signed a memorandum of understanding with ATLATL to expand its global open innovation efforts. Under the agreement, Samsung Bioepis identifies promising biotech startups and supports their early-stage development through access to ATLATL's shared laboratories, office space, and CRO services across key biotech clusters including Beijing, Shanghai, Singapore, and Australia. This marks Samsung Bioepis' first open innovation collaboration with an overseas specialized institution. In June 2026, the two companies launched the 'Samsung Bioepis Innovation Prize C-Lab Outside' targeting early-stage biotech companies across the Asia-Pacific region in therapeutic areas including oncology, immunology, inflammation, and metabolic diseases, with selected companies gaining access to ATLATL's laboratory infrastructure, mentorship, and potential collaboration with Samsung Bioepis.
• Daiichi SankyocoreStrategic or Co-development Partner · 8 April 2026ATLATL and Daiichi Sankyo entered a partnership agreement to leverage ATLATL's multi-regional Asia-Pacific R&D network to help Daiichi Sankyo identify high-quality R&D platform technologies and accelerate innovative science. ATLATL operates innovation centers across Shanghai, Beijing, Shenzhen, Hong Kong, and Singapore, offering full-chain services from resource matching to cooperation implementation for biotech startups and growth-stage companies. The collaboration aims to bring new treatment options to patients worldwide by connecting global innovation resources through ATLATL's engineered life science platform.
• ServiercoreStrategic or Co-development PartnerATLATL has a dedicated Servier venture page on its website, indicating a partnership focused on identifying early-stage pharmaceutical R&D innovation projects from China's life science community, finding innovative collaborations, and serving Servier's China 2030 R&D strategy. The program targets Greater China's biotech companies (startups), universities, research institutes, and medical institutions, focusing on precision medicine projects in oncology and neuroscience, novel therapeutic modalities, and AI/digital drug discovery technologies. Winning projects receive 800,000 RMB in rewards for ATLATL lab space and R&D services.
• Charles River (CRADL)strategicTechnology or IntegrationATLATL partners with Charles River Laboratories through the CRADL (Charles River Accelerator & Development Lab) program, providing fully equipped vivarium/animal research facilities with comprehensive technical support for preclinical studies. The partnership supports startups and established biotech/pharma companies with flexible solutions including rack-level, room-level, and private suite vivarium spaces.
• Miltenyi BiotecsupportingTechnology or IntegrationATLATL collaborates with Miltenyi Biotec for cell biology research platforms, utilizing equipment including MACSQuant Analyzer X, MACSQuant Analyzer 10, MACSQuant Analyzer 16, MACSQuant VYB, MACSQuant Tyto, CliniMACS Prodigy, and GentleMACS Octo Dissociator for cell engineering, FACS sorting, and cell therapy development.
• NikonsupportingTechnology or IntegrationATLATL uses Nikon equipment across its imaging platforms including Nikon AX confocal laser scanning microscope, Nikon ECLIPSE Ts2-FL, Nikon Eclipse Ti2-U inverted fluorescence microscope, Nikon Ts2R-FL inverted fluorescence microscope, Nikon Ci-L upright fluorescence microscope, Nikon Ni-U upright fluorescence microscope, and Nikon AX confocal laser scanning microscope, supporting high-content imaging and live cell imaging workflows.
• Bruker / VizgensupportingTechnology or IntegrationATLATL partners with Bruker/Vizgen for single-cell and spatial biology research, utilizing the Vizgen MERSCOPE Ultra and Bruker CosMx Spatial Molecular Imager for spatial transcriptomics and multi-omics analysis at the Single Cell Research Center.
• RevvitysupportingTechnology or IntegrationATLATL uses Revvity equipment for drug screening and imaging, including Revvity Janus G3 and Zephyr workstations, EnVision microplate reader, Operetta CLS high-content imaging system, Cellometer K2 fluorescent cell counter, and IVIS Lumina III in-vivo imaging system.
• Thermo Fisher ScientificsupportingTechnology or IntegrationATLATL uses Thermo Fisher Scientific equipment including Countess 3 automated cell counter, NanoDrop OneC spectrophotometer, SimpliAmp gradient PCR instrument, iBind Flex Western blot, and iBlot 3 transfer system for cell biology, genomics, and proteomics workflows.
• Akoya BiosciencessupportingTechnology or IntegrationATLATL uses Akoya Biosciences Mantra 2 quantitative pathology imaging and analysis system at its imaging center for multi-plex immunofluorescence and high-content tissue analysis.
• TecansupportingTechnology or IntegrationATLATL collaborates with Tecan for cell biology research platforms including Spark Cyto microplate reader and Fluent automated liquid handling, supporting high-throughput screening workflows.
• Miltenyi Biotec Cell & Gene Therapy PlatformsupportingTechnology or IntegrationATLATL operates a Cell Manufacturing Center utilizing Miltenyi Biotec's CliniMACS Plus and CliniMACS Prodigy platforms for T cell isolation, NK cell enrichment, Treg separation, B cell depletion/enrichment, and HSC CD34 enrichment for cell therapy manufacturing.

Scale indicators3 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• BioLabs: International network of shared lab/co-working spaces for life science startups across the US and Europe. Directly comparable co-working lab model with site-based membership and partner ecosystem.
• Alexandria LaunchLabs: Alexandria Real Estate's shared lab and office platform for early-stage life science companies. Comparable turnkey lab SaaS with capital-efficient startup infrastructure.
• JLABS (Johnson & Johnson Innovation): J&J's global life science incubator network offering no-strings-attached lab space, equipment, and corporate partnerships to early-stage biotech. Directly comparable to ATLATL's model of shared Class A labs plus pharma open-innovation programs.
• LabCentral: Non-profit biotech incubator in Cambridge/Boston providing shared lab space, services, and a network of sponsor companies. Highly comparable shared-lab-as-a-service model serving early-stage life science ventures.
• MBC BioLabs: San Francisco Bay Area biotech incubator offering fully equipped lab space and operational support to early-stage companies. Closely comparable in shared lab SaaS model and startup-focused value proposition.

Broad incumbents

• Charles River Laboratories: Global CRO offering preclinical, clinical, and manufacturing services. ATLATL partners with Charles River via CRADL; comparable on the contract research and lab services side, but at vastly greater scale and breadth.
• WuXi AppTec: China-headquartered global CRO/CDMO offering discovery, development, and manufacturing services. Overlaps with ATLATL's CRO and lab services in APAC and is the dominant scaled competitor in the region.

Emerging players

• The Engine (MIT): Venture firm and Tough Tech hub spun out of MIT providing infrastructure and capital to science-driven startups. Adjacent in mission and shared infrastructure model, though focused on broader Tough Tech rather than life sciences only.

Others

• QIMR Berghofer Medical Research Institute: Australian medical research institute where ATLATL's Brisbane innovation center is co-located. Functions as an institutional host/partner enabling ATLATL's Australian footprint and providing research ecosystem access.

Regional players

• GenScript: Asia-based life science services and bio-tools provider offering gene synthesis, protein services, and cell therapy platforms. Comparable on the gene/protein service and cell biology platform offerings within ATLATL's portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/atlatlcenter

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ATLATL Innovation Center